Pharmaceuticals

Ischemic Heart Disease (IHD) Drugs Market Expansion to $3.2 Billion by 2029: Key Drivers and Trends

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the ischemic heart disease (ihd) drugs market from 2025–2034 with trusted insights from The Business Research Company

What Is The Base Market Size For The Ischemic Heart Disease (IHD) Drugs Market Today And What Will It Reach By 2029?

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market has experienced substantial growth in recent years. Its size is anticipated to expand from $2.44 billion in 2024 to $2.57 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.3%. This historic growth can be attributed to the rising prevalence of autoimmune diseases, increased investment in autoimmune drug development, expansion of indications, growing awareness of autoimmune disease management, and rising healthcare expenditure.

The sphingosine 1 phosphate receptor (S1PR) modulator drugs market is anticipated to experience substantial expansion in the coming years, projected to reach $3.2 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.6%. This expansion during the forecast period is driven by several factors, including a heightened preference for oral treatments over injectable ones, the increasing incidence of autoimmune conditions, a global rise in healthcare spending, enhanced awareness and diagnostic rates for diseases such as multiple sclerosis, and an expanding elderly demographic more susceptible to autoimmune disorders. Key developments expected during this period involve progress in receptor selectivity, securing regulatory approvals for new therapeutic uses, incorporating real-world evidence (RWE), innovations in drug delivery technologies, a move towards oral administration, and an increase in strategic partnerships and company acquisitions.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21288&type=smp

What Factors Are Boosting The Ischemic Heart Disease (IHD) Drugs Market?

The expanding occurrence of autoimmune conditions is anticipated to drive the expansion of the sphingosine 1 phosphate receptor (S1PR) modulator drugs market in the future. These illnesses involve the immune system erroneously targeting the body’s healthy tissues, resulting in inflammation and harm. The increasing incidence of autoimmune diseases stems from genetic predispositions, environmental stimuli, evolving lifestyles, and enhanced diagnostic capabilities. Sphingosine 1-Phosphate Receptor (S1PR) modulator drugs are employed in treating autoimmune disorders to control the movement of immune cells, thereby diminishing inflammation in ailments such as multiple sclerosis and ulcerative colitis. For example, data released by the National Center for Health Statistics (NCHS), a US-based health statistics agency, in May 2024, indicated that the proportion of adults aged 18 and above in the United States with current asthma climbed from 8.4% in 2021 to 8.7% in 2022. Furthermore, the occurrence of asthma episodes among adults in that same age bracket over the previous 12 months saw an increase from 3.3% in 2021 to 3.7% in 2022. Consequently, the growing frequency of autoimmune diseases is fueling the expansion of the sphingosine 1-phosphate receptor (S1PR) modulator drugs market.

How Is The Ischemic Heart Disease (IHD) Drugs Market Categorized By Application, Type, And Region?

The sphingosine 1 phosphate receptor (s1pr) modulator drugs market covered in this report is segmented –

1) By Type: Fingolimod, Ozanimod

2) By Route Of Administration: Oral, Injectable, Topical

3) By Application: Multiple Sclerosis, Cardiovascular Diseases, Transplant Rejection

4) By End User: Hospital, Rehabilitation Centres, Retail Pharmacies

Subsegments:

1) By Fingolimod: Branded Formulations, Generic Formulations

2) By Ozanimod: Oral Capsules, Other Formulations

How Are Technological Trends Affecting The Ischemic Heart Disease (IHD) Drugs Market Growth?

Companies operating within the sphingosine 1 phosphate receptor (S1PR) modulator drugs market are focusing on innovative therapies, such as oral therapy, to improve patient compliance, enhance drug efficacy, and broaden the therapeutic potential of S1PR modulator drugs for treating autoimmune diseases and related conditions. Oral therapy involves administering these medications in pill or tablet form, offering a convenient and less invasive treatment method for individuals with autoimmune diseases. For instance, in March 2022, Pfizer, a US-based pharmaceutical and biotechnology company, reported favorable phase 3 trial results for etrasimod in ulcerative colitis patients. The drug successfully met its primary and key secondary endpoints, demonstrating significant improvements in remission, endoscopic outcomes, and symptom relief. These findings underscore etrasimod’s potential as a new treatment for moderate-to-severe ulcerative colitis. Pfizer aims to advance regulatory submissions, which will strengthen its immuno-inflammatory disease portfolio. These results reaffirm the company’s commitment to delivering innovative healthcare solutions.

Who Are The Global Leaders Steering The Ischemic Heart Disease (IHD) Drugs Market Forward?

Major companies operating in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, Novartis International AG, Biogen Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ono Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., KYORIN Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., Celgene Corporation, Ventyx Biosciences Inc., Idorsia Pharmaceuticals Ltd., Cayman Chemical Company, Juvisé Pharmaceuticals, Priothera Limited, Arena Pharmaceuticals.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/sphingosine-1-phosphate-receptor-s1pr-modulator-drugs-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Ischemic Heart Disease (IHD) Drugs Market?

Asia-Pacific was the largest region in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market in 2024. The regions covered in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=21288&type=smp

Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2025, By The Business Research Company

Hyperphosphatemia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hyperphosphatemia-treatment-global-market-report

Phosphate Fertilizer Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/phosphate-fertilizer-global-market-report

Lithium Iron Phosphate Battery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lithium-iron-phosphate-battery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795